Thrombophilia encompasses a spectrum of disorders characterized by a predisposition to a hypercoagulable state,frequently culminating in thromboembolism.1 Among these,hereditary thrombophilia is defined as conditions ...Thrombophilia encompasses a spectrum of disorders characterized by a predisposition to a hypercoagulable state,frequently culminating in thromboembolism.1 Among these,hereditary thrombophilia is defined as conditions arising from genetic mutations that disrupt hemostatic equilibrium.The clinical manifestations of thrombophilia primarily involve venous thromboembolism(VTE).Certain genetic variants may also predispose individuals to arterial thrombotic events.While previous articles have provided guidance on indications for thrombophilia screening,discussions are largely confined to whether such screening informs the“duration of anticoagulation therapy.”1 This guideline,focusing specifically on hereditary thrombophilia,seeks to delineate the impact of diverse genetic factors on the selection of anticoagulant drug types and their duration.This work primarily addresses major hereditary thrombophilias.Gene polymorphisms with minimal contributions to disease,such as those associated with the ABO blood group,as well as exceedingly rare genetic mutations like F9 Padua,are not discussed here due to their limited clinical relevance or scant supporting evidence.The panel adopts the 2011 Oxford Center for Evidence-Based Medicine framework to assess the level of evidence(LoE)and make recommendations.展开更多
Thrombotic diseases,a class of circulatory system disorders characterized by the abnormal coagulation of blood within arterial and venous vessels,leading to partial or complete vascular occlusion,represent a major glo...Thrombotic diseases,a class of circulatory system disorders characterized by the abnormal coagulation of blood within arterial and venous vessels,leading to partial or complete vascular occlusion,represent a major global cause of mortality and morbidity.Considering the inefficacy of thrombolytic therapies and high incidence of complications,these diseases pose significant healthcare challenges.Nanotechnology,distinguished by its precise targeting,on-demand drug release,reduced dosage,and lower risk of hemorrhagic complications,offers unique advantages for the diagnosis and treatment of thrombotic disorders.As a cutting-edge technology,micro/nano-robots are novel therapeutic options for managing these conditions.This review elucidates the mechanisms of thrombus formation,discusses the efficacy and limitations of traditional antithrombotic drugs,summarizes research advancements in nanomaterials and micro/nanorobots for thrombotic diseases,and presents their promising clinical translation prospects.展开更多
基金supported by the Chang Jiang Scholars Program(No.2022161).
文摘Thrombophilia encompasses a spectrum of disorders characterized by a predisposition to a hypercoagulable state,frequently culminating in thromboembolism.1 Among these,hereditary thrombophilia is defined as conditions arising from genetic mutations that disrupt hemostatic equilibrium.The clinical manifestations of thrombophilia primarily involve venous thromboembolism(VTE).Certain genetic variants may also predispose individuals to arterial thrombotic events.While previous articles have provided guidance on indications for thrombophilia screening,discussions are largely confined to whether such screening informs the“duration of anticoagulation therapy.”1 This guideline,focusing specifically on hereditary thrombophilia,seeks to delineate the impact of diverse genetic factors on the selection of anticoagulant drug types and their duration.This work primarily addresses major hereditary thrombophilias.Gene polymorphisms with minimal contributions to disease,such as those associated with the ABO blood group,as well as exceedingly rare genetic mutations like F9 Padua,are not discussed here due to their limited clinical relevance or scant supporting evidence.The panel adopts the 2011 Oxford Center for Evidence-Based Medicine framework to assess the level of evidence(LoE)and make recommendations.
基金supported by the National Key R&D Program of China(2022YFC2304600)National Natural Science Foundation of China(No.82170131 and No.82470134)Young Top-notch Talent Cultivation Program of Hubei Province 202117.
文摘Thrombotic diseases,a class of circulatory system disorders characterized by the abnormal coagulation of blood within arterial and venous vessels,leading to partial or complete vascular occlusion,represent a major global cause of mortality and morbidity.Considering the inefficacy of thrombolytic therapies and high incidence of complications,these diseases pose significant healthcare challenges.Nanotechnology,distinguished by its precise targeting,on-demand drug release,reduced dosage,and lower risk of hemorrhagic complications,offers unique advantages for the diagnosis and treatment of thrombotic disorders.As a cutting-edge technology,micro/nano-robots are novel therapeutic options for managing these conditions.This review elucidates the mechanisms of thrombus formation,discusses the efficacy and limitations of traditional antithrombotic drugs,summarizes research advancements in nanomaterials and micro/nanorobots for thrombotic diseases,and presents their promising clinical translation prospects.
